Incyte (INCY) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Incyte (INCY) do?
Incyte Corp (INCY) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops and sells prescription medicines for rare blood cancers and autoimmune skin disorders. Generates revenue through direct pharmaceutical sales and global commercial partnerships. The company discovers and commercializes proprietary oral and topical medicines for blood cancers and inflammatory skin. It is worth $23.62B on the market and sold $6.01B over the last year.
- Market cap
- $23.62B
- P/E ratio
- 61.7×
- Annual sales
- $6.01B
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 12, 2026
Brands and businesses behind INCY
- Jakafi: Treats specific bone marrow disorders and graft-versus-host disease through prescription tablet sales in the United States.
- Opzelura: Generates revenue by selling a topical prescription cream for atopic dermatitis and nonsegmental vitiligo.
- Pemazyre: Earns revenue from sales of oral tablets treating adults with previously treated, unresectable bile duct cancer.
- Zynyz: Earns sales as an infused immunotherapy for adults with metastatic or recurrent Merkel cell carcinoma.
INCY’s flags, in plain English
Each flag is a number from Incyte’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Low debt
Low debt, only 1% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 91.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Stupid Cash
Can pay this year's bills 3.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Priced for Perfection
Priced at 61.7 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
1 more green flag open with the free trial. Try it free for 7 days.
Questions about INCY
How big is Incyte?
Incyte’s market cap is $23.62B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $6.01B: what customers paid the company over the last year, before any costs.
What is INCY’s P/E ratio?
INCY’s P/E ratio is 61.7×. Investors pay about 61.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with INCY?
A single blood cancer drug, Jakafi, accounts for the majority of the company's total annual product revenue. That is one risk on Incyte’s card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Incyte’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. INCY’s filings on SEC.gov. The Margin Monkey is research, not advice.
